Scarica l'app Stockscreener
0.771
1.43%
0.0109
Io Biotech Inc Borsa (IOBT) Ultime notizie
IO Biotech announces up to €57.5M debt financing from the European Investment Bank - MSN
IO Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank - citybiz
IO Biotech secures €57.5 million EIB loan for cancer vaccines By Investing.com - Investing.com Canada
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Marketscreener.com
IO Biotech Secures €57.5M EIB Loan Facility to Advance Cancer Vaccine Development Pipeline - StockTitan
IO Biotech (NASDAQ:IOBT) Trading Down 1.3%Here's Why - MarketBeat
IO Biotech (NASDAQ:IOBT) Shares Down 1.3% – Here’s What Happened - Defense World
IO Biotech amends bylaws and adjusts fiscal year-end - Investing.com
IO Biotech : Amendments to Bylaws Form 8 K - Marketscreener.com
IO Biotech amends bylaws and adjusts fiscal year-end By Investing.com - Investing.com UK
Cancer Vaccines Pipeline Drugs Analysis Report, 2024: FDA - openPR
(PDF) 756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC) - ResearchGate
Cancer Vaccines Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - Barchart
Cancer Vaccines Market Forecasted to Surge in Coming Years, - openPR
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight - Barchart
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: - openPR
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
IO Biotech stock hits 52-week low at $0.73 amid market challenges - Investing.com UK
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
HC Wainwright Decreases Earnings Estimates for IO Biotech - MarketBeat
Neuronetics (NASDAQ: STIM) Announces Key Financial Updates and FDA Clearance for Adolescent Treatment - Defense World
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Receives $62.50 Average Price Target from Analysts - Defense World
IO Biotech (NASDAQ:IOBT) Given "Buy" Rating at HC Wainwright - MarketBeat
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences - The Manila Times
IO Biotech Reports Advancing Cancer Trials Despite Widening Q3 Losses; Cash Position at $80.2M | IOBT Stock News - StockTitan
IO Biotech Announces Participation in Upcoming Investor Conferences - Marketscreener.com
IO Biotech to Present at Jefferies, Piper Sandler Healthcare Conferences | IOBT Stock News - StockTitan
Asia stocks fall as China stimulus disappoints, deflation persists - Investing.com
IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103 - Marketscreener.com
Promising results for IO Biotech’s cancer vaccine By Investing.com - Investing.com Canada
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study - ForexTV.com
IO Biotech's Cancer Vaccine Shows 81% Disease Control Rate in Lung Cancer Trial | IOBT Stock News - StockTitan
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation - Yahoo Finance
Legend Biotech Chooses Philadelphia for New R&D Center - BioBuzz
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 12.7% - MarketBeat
Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
IO Biotech, Inc. (NASDAQ:IOBT) Shares Sold by Novo Holdings A S - MarketBeat
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable - GlobeNewswire
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, Companies by DelveInsight - Barchart
38,076 Shares in Montauk Renewables, Inc. (NASDAQ:MNTK) Bought by Squarepoint Ops LLC - Defense World
Bank of America Boosts Voya Financial (NYSE:VOYA) Price Target to $88.00 - Defense World
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Norstella introduces a fully integrated data asset for biopharma - European Pharmaceutical Manufacturer
Immuno-Oncology Clinical Trials Market Valuation to Reach $18.1 Billion By 2032 - 대구포스트
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - ForexTV.com
VerImmune Secures $4.5 Million to Drive Biotech Innovation - BioBuzz
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - The Manila Times
ARHT Media Inc. Announces Filing for Bankruptcy - The Manila Times
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting - Marketscreener.com
United States shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
5 Best Microbiome Companies (December 2024) - Securities.io
ProShare Advisors LLC Sells 113 Shares of Reinsurance Group of America, Incorporated (NYSE:RGA) - Defense World
Novo Holdings A S Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT) - MarketBeat
American Century Companies Inc. Purchases 75,475 Shares of Lifetime Brands, Inc. (NASDAQ:LCUT) - Defense World
PCI Pharma Services invests over $365 million in EU and US facilities - European Pharmaceutical Manufacturer
Sei Investments Co. Buys 24,363 Shares of IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Cancer Vaccines Market Detailed In Recent Development to Grow - openPR
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):